The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with renal cell carcinoma was developed by the Society for Immunotherapy of Cancer (SITC) and published online by the Journal for ImmunoTherapy of Cancer, in 2016.
This consensus statement provides expert evidence-based recommendations for the use of cytokine-based immunotherapies, IL-2 and IFN, and the more recently approved drug, nivolumab, a checkpoint inhibitor. This statement includes recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapies.